🇺🇸 Lanreotide ATG in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Abdominal Pain Upper — 1 report (10%)
2. Alanine Aminotransferase Increased — 1 report (10%)
3. Alopecia — 1 report (10%)
4. Anxiety — 1 report (10%)
5. Aphthous Ulcer — 1 report (10%)
6. Back Pain — 1 report (10%)
7. Dry Skin — 1 report (10%)
8. Eyelid Oedema — 1 report (10%)
9. Femoral Neck Fracture — 1 report (10%)
10. Flatulence — 1 report (10%)

Source database →

Frequently asked questions

Is Lanreotide ATG approved in United States?

Lanreotide ATG does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Lanreotide ATG in United States?

Camurus AB is the originator. The local marketing authorisation holder may differ — check the official source linked above.